Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-7.36M | $-0.23 |
| 2024 | $3.50M | $-5.81M | $-0.20 |
| 2023 | $2.90M | $-6.80M | $-0.24 |
| 2022 | $2.93M | $-9.74M | $-0.34 |
| 2021 | $2.40M | $-13.07M | $-0.47 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.03 per share
Typical surprise -37.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.06 vs $-0.04miss
- Wed, May 13$-0.05 vs $-0.04miss
- Wed, Mar 25$-0.06 vs $-0.03miss
- Wed, Nov 12$-0.06 vs $-0.04miss
- Wed, Aug 13$-0.06 vs $-0.06beat
- Wed, Mar 26$-0.05 vs $-0.04miss
Estimates and results for DYAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
DYAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·2d ago·Positive
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·3d ago·Negative
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June
View source ↗